<DOC>
	<DOCNO>NCT00607789</DOCNO>
	<brief_summary>The purpose research study test safety duloxetine see effect ( good bad ) subject 's binge eat disorder comorbid depressive disorder ( depression occur binge eat disorder ) compare placebo ( inactive pill ) .</brief_summary>
	<brief_title>Study Duloxetine v Placebo Treatment Binge Eating Disorder With Depression</brief_title>
	<detailed_description>This 12-week , double blind , randomize , placebo-controlled , parallel-group , flexible-dose study duloxetine 60-120 mg/day patient BED comorbid depressive disorder . Patients randomly assign either duloxetine 30 mg capsule match placebo baseline visit . The initial dose study medication one 30 mg duloxetine capsule/day placebo plan increase 60 mg/day ( 2 X 30 mg ) match placebo end week 1 . Further dose increase 30 mg 120 mg/day allow end week two base investigator ' assessment efficacy tolerability . Dosing either per day twice day depend tolerability . Patient visit occur screen baseline end week 1 , 2 , 4 , 6 , 8 , 10 , 12 . Study drug taper 30 mg every 3 day end study .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Feeding Eating Disorders</mesh_term>
	<mesh_term>Binge-Eating Disorder</mesh_term>
	<mesh_term>Bulimia</mesh_term>
	<mesh_term>Duloxetine Hydrochloride</mesh_term>
	<criteria>Inclusion criterion : Subjects must provide write informed consent free . Male female outpatient . Age 1865 year , inclusive . Subject must meet DSMIV criterion diagnosis depressive disorder ( major depression , dysthymia , minor depression , brief recurrent depression ) duration least 1 month precede screening period . Subjects must meet DSMIV criterion diagnosis binge eat disorder ( BED ) least last 6 month . The DSMIV criterion follow : 1 . Recurrent episodes binge eat . 2 . The binge eat episode associate least three follow : eat much rapidly normal ; eat uncomfortably full ; eat large amount food feeling physically hungry ; eat alone embarrass much one eating ; feel disgust oneself , depress , feel guilty overeating . 3 . Marked distress regard binge eating . 4 . The binge eating occur , average , least two day week past six month . 5 . The episodes binge eat occur exclusively course bulimia nervosa anorexia nervosa . Subjects IDS score least 25 baseline visit . Women pregnant , breastfeeding , childbearing potential use medically acceptable , effective method birth control . Women childbearing potential include premenopausal woman biologically capable become pregnant contribute fertilizable ovum . Medically acceptable method birth control include oral contraceptive , intrauterine device , use two combine barrier method , surgical sterilization . Patients display significant risk suicide . Patients receive psychotherapy behavioral therapy mental health professional part previous treatment MDD obesity least 3 month prior randomization . A DSMIV diagnosis alcohol substance abuse dependence , bulimia nervosa , anorexia nervosa within 6 month prior randomization . Patients lifetime DSMIV history psychotic disorder , bipolar disorder , dementia . Patients history psychosurgery Patients Axis II disorder ( personality disorder schizotypal , borderline , antisocial ) , might interfere diagnostic assessment , treatment , compliance . Patients clinically unstable medical disease . Patients hepatic insufficiency Patients endstage renal disease severe renal impairment Patients history seizure , include febrile seizure childhood . Patients require treatment drug might interact adversely obscure action study medication . Patients know hypersensitivity duloxetine inactive ingredient duloxetine ( Cymbalta ) . Patients uncontrolled narrowangle glaucoma . Patients clinically relevant abnormal laboratory result , specifically include hypokalemia . Patients receive monoamine oxidase inhibitor , tricyclic , antipsychotic , lithium , fluoxetine within four week prior randomization . Patients receive psychoactive medication ( include appetite suppressant ) antiobesity medication within one week prior randomization . Patients receive investigational medication depot neuroleptic within three month prior randomization . Patients previously enrol study previously treat duloxetine . Subject consider investigator unable follow throughout entire duration study . Patients take medication inhibit P4502D6 hepatic isoenzyme</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2012</verification_date>
</DOC>